Category: BioTech

Gilead Sciences GILD NASDAQ:GILD
Analysis, BioTech, Diversified Tech, Finance, Mergers & Acquisitions, Semiconductors, Services Sector, software, Software, Tech IPO

Saenz Steps Down as Santander CEO

On Monday, Banco Santander SAN announced that Alfredo Saenz has resigned as CEO ahead of a decision by Spanish regulators that would have effectively decided whether his criminal conviction should disallow him from working in banking. Until recently, Spain’s rules had prevented anyone with a criminal conviction from holding a senior position in banking. Saenz was convicted in 2009 of making false criminal acquisitions against … Continue reading Saenz Steps Down as Santander CEO

John MeadyLeave a comment
Biotech stock market news
BioTech, Finance

Biotech Stocks Highlight for the Week: Achillion Pharmaceuticals Soars Due to Positive Test Results

Achillion Pharmaceuticals, Inc (ACHN) reported positive interim results from a phase II study (n=12) on its hepatitis C virus (HCV) candidate, ACH-3102. The company’s shares jumped 9.6% following the news. The mid-stage study is evaluating a ribavirin-free regimen of ACH-3102 in combination with Gilead’s (GILD) Sovaldi (sofosbuvir) for the treatment of patients suffering from treatment-naïve genotype 1 chronic HCV infection for eight weeks. Results from … Continue reading Biotech Stocks Highlight for the Week: Achillion Pharmaceuticals Soars Due to Positive Test Results

Richard Atkins
BioTech, Finance

Biotech Stock Update: Biotech Stock Gilead Scores Legal Victory Over Roche for Sovaldi

Shares of Gilead Sciences (GILD) gained 3.25% to close the trading session on Aug 15 at $99.45 per share following the favorable verdict by an arbitration panel in a patent infringement case with Roche (RHHBY). The tussle was regarding Gilead’s blockbuster hepatitis C drug, Sovaldi (sofosbuvir). Gilead received further encouraging news on Sovaldi when U.K.’s cost-effectiveness watchdog – NICE – recommended the use of the … Continue reading Biotech Stock Update: Biotech Stock Gilead Scores Legal Victory Over Roche for Sovaldi

Richard Atkins
Gilead Sciences GILD NASDAQ:GILD
Analysis, BioTech, Diversified Tech, Finance, Global Equity, Mergers & Acquisitions, Semiconductors, Services Sector, software, Software, Tech IPO

Rumors Suggest Surprising Possibility of Valeant and Actavis Combination

Media reports over the weekend suggested Valeant Pharmaceuticals VRX held merger discussions with Actavis ACT , which may now have stalled on financial considerations. Valeant had been signaling that it was seeking to pursue a large acquisition or a merger of equals, so the magnitude of the deal was not surprising, but we were a little surprised by the target. Overall, there may be enough … Continue reading Rumors Suggest Surprising Possibility of Valeant and Actavis Combination

John MeadyLeave a comment
BioTech, Finance

Biotech News: Top Stocks Review For The Week

The trading session has ended on a higher note as the Dow Jones Industrial Average finished at 16,569.98, up 0.10% and the NASDAQ Composite closed at 4,401.33, up 0.70%. The S&P 500 finished the day 0.28% higher at 1,936.92. During the trading session seven out of ten sectors finished on a positive note. The S&P 500 Health Care Sector Index finished the day at 700.04, … Continue reading Biotech News: Top Stocks Review For The Week

Richard Atkins
Gilead Sciences GILD NASDAQ:GILD
Analysis, BioTech, Diversified Tech, Finance, Mergers & Acquisitions, Semiconductors, Services Sector, Software, software, Tech IPO

White Mountains’ Underwriting Margins Drive 1Q Book Value Increase

A benign catastrophe season and continued improvement in underwriting margins at majority-owned OneBeacon OB led to a 3% sequential increase in adjusted book value to $606 per share at White Mountains Insurance Group WTM . In comparison with last year’s first quarter, the combined ratio (expense divided by earned premiums) fell to 81% from 84% at Sirius Group, White Mountains’ reinsurance subsidiary, while OneBeacon also … Continue reading White Mountains’ Underwriting Margins Drive 1Q Book Value Increase

John MeadyLeave a comment